Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
Employer-insured enrollees spend more on prescriptions than health-insurance exchange enrollees, but the groups spend the same amount of money when it comes to specialty medications, a study shows.
Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression
Value is a concept that concerns all healthcare stakeholders.
- Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs
- When it comes to PCSK9s, payers resisted — and sales flopped
- Five things for pharma marketers to know: Thursday, January 12, 2017
- Infographic: Can pharma give doctors what they want?
- Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?
- Five things for pharma marketers to know: Tuesday, January 17, 2017
- Trump administration raises questions for rare-disease drugmakers
- If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold
- Five things for pharma marketers to know: Friday, January 13, 2017
- Klick Health's Elliot Langerman on the Power of Persuasion